Cargando…
Vaccine Candidate Against COVID-19 Based on Structurally Modified Plant Virus as an Adjuvant
A recombinant vaccine candidate has been developed based on the major coronaviruses’ antigen (S protein) fragments and a novel adjuvant—spherical particles (SPs) formed during tobacco mosaic virus thermal remodeling. The receptor-binding domain and the highly conserved antigenic fragments of the S2...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919459/ https://www.ncbi.nlm.nih.gov/pubmed/35295298 http://dx.doi.org/10.3389/fmicb.2022.845316 |
_version_ | 1784668945678073856 |
---|---|
author | Kovalenko, Angelina O. Ryabchevskaya, Ekaterina M. Evtushenko, Ekaterina A. Manukhova, Tatiana I. Kondakova, Olga A. Ivanov, Peter A. Arkhipenko, Marina V. Gushchin, Vladimir A. Nikitin, Nikolai A. Karpova, Olga V. |
author_facet | Kovalenko, Angelina O. Ryabchevskaya, Ekaterina M. Evtushenko, Ekaterina A. Manukhova, Tatiana I. Kondakova, Olga A. Ivanov, Peter A. Arkhipenko, Marina V. Gushchin, Vladimir A. Nikitin, Nikolai A. Karpova, Olga V. |
author_sort | Kovalenko, Angelina O. |
collection | PubMed |
description | A recombinant vaccine candidate has been developed based on the major coronaviruses’ antigen (S protein) fragments and a novel adjuvant—spherical particles (SPs) formed during tobacco mosaic virus thermal remodeling. The receptor-binding domain and the highly conserved antigenic fragments of the S2 protein subunit were chosen for the design of recombinant coronavirus antigens. The set of three antigens (Co1, CoF, and PE) was developed and used to create a vaccine candidate composed of antigens and SPs (SPs + 3AG). Recognition of SPs + 3AG compositions by commercially available antibodies against spike proteins of SARS-CoV and SARS-CoV-2 was confirmed. The immunogenicity testing of these compositions in a mouse model showed that SPs improved immune response to the CoF and PE antigens. Total IgG titers against both proteins were 9–16 times higher than those to SPs. Neutralizing activity against SARS-CoV-2 in serum samples collected from hamsters immunized with the SPs + 3AG was demonstrated. |
format | Online Article Text |
id | pubmed-8919459 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89194592022-03-15 Vaccine Candidate Against COVID-19 Based on Structurally Modified Plant Virus as an Adjuvant Kovalenko, Angelina O. Ryabchevskaya, Ekaterina M. Evtushenko, Ekaterina A. Manukhova, Tatiana I. Kondakova, Olga A. Ivanov, Peter A. Arkhipenko, Marina V. Gushchin, Vladimir A. Nikitin, Nikolai A. Karpova, Olga V. Front Microbiol Microbiology A recombinant vaccine candidate has been developed based on the major coronaviruses’ antigen (S protein) fragments and a novel adjuvant—spherical particles (SPs) formed during tobacco mosaic virus thermal remodeling. The receptor-binding domain and the highly conserved antigenic fragments of the S2 protein subunit were chosen for the design of recombinant coronavirus antigens. The set of three antigens (Co1, CoF, and PE) was developed and used to create a vaccine candidate composed of antigens and SPs (SPs + 3AG). Recognition of SPs + 3AG compositions by commercially available antibodies against spike proteins of SARS-CoV and SARS-CoV-2 was confirmed. The immunogenicity testing of these compositions in a mouse model showed that SPs improved immune response to the CoF and PE antigens. Total IgG titers against both proteins were 9–16 times higher than those to SPs. Neutralizing activity against SARS-CoV-2 in serum samples collected from hamsters immunized with the SPs + 3AG was demonstrated. Frontiers Media S.A. 2022-02-28 /pmc/articles/PMC8919459/ /pubmed/35295298 http://dx.doi.org/10.3389/fmicb.2022.845316 Text en Copyright © 2022 Kovalenko, Ryabchevskaya, Evtushenko, Manukhova, Kondakova, Ivanov, Arkhipenko, Gushchin, Nikitin and Karpova. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Microbiology Kovalenko, Angelina O. Ryabchevskaya, Ekaterina M. Evtushenko, Ekaterina A. Manukhova, Tatiana I. Kondakova, Olga A. Ivanov, Peter A. Arkhipenko, Marina V. Gushchin, Vladimir A. Nikitin, Nikolai A. Karpova, Olga V. Vaccine Candidate Against COVID-19 Based on Structurally Modified Plant Virus as an Adjuvant |
title | Vaccine Candidate Against COVID-19 Based on Structurally Modified Plant Virus as an Adjuvant |
title_full | Vaccine Candidate Against COVID-19 Based on Structurally Modified Plant Virus as an Adjuvant |
title_fullStr | Vaccine Candidate Against COVID-19 Based on Structurally Modified Plant Virus as an Adjuvant |
title_full_unstemmed | Vaccine Candidate Against COVID-19 Based on Structurally Modified Plant Virus as an Adjuvant |
title_short | Vaccine Candidate Against COVID-19 Based on Structurally Modified Plant Virus as an Adjuvant |
title_sort | vaccine candidate against covid-19 based on structurally modified plant virus as an adjuvant |
topic | Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919459/ https://www.ncbi.nlm.nih.gov/pubmed/35295298 http://dx.doi.org/10.3389/fmicb.2022.845316 |
work_keys_str_mv | AT kovalenkoangelinao vaccinecandidateagainstcovid19basedonstructurallymodifiedplantvirusasanadjuvant AT ryabchevskayaekaterinam vaccinecandidateagainstcovid19basedonstructurallymodifiedplantvirusasanadjuvant AT evtushenkoekaterinaa vaccinecandidateagainstcovid19basedonstructurallymodifiedplantvirusasanadjuvant AT manukhovatatianai vaccinecandidateagainstcovid19basedonstructurallymodifiedplantvirusasanadjuvant AT kondakovaolgaa vaccinecandidateagainstcovid19basedonstructurallymodifiedplantvirusasanadjuvant AT ivanovpetera vaccinecandidateagainstcovid19basedonstructurallymodifiedplantvirusasanadjuvant AT arkhipenkomarinav vaccinecandidateagainstcovid19basedonstructurallymodifiedplantvirusasanadjuvant AT gushchinvladimira vaccinecandidateagainstcovid19basedonstructurallymodifiedplantvirusasanadjuvant AT nikitinnikolaia vaccinecandidateagainstcovid19basedonstructurallymodifiedplantvirusasanadjuvant AT karpovaolgav vaccinecandidateagainstcovid19basedonstructurallymodifiedplantvirusasanadjuvant |